Finally, although the EpiView-D4 was able to distinguish clinically HER2-positive specimens from HER2-negative and non-tumor specimens in this study, work remains to be done with larger sample sizes in order to adequately calculate the clinical sensitivity/specificity and to establish appropriate diagnostic cut-off points based on receiver-operator characteristics. The gene discussed is ERBB2; the disease is neoplasm.